Sanofi India Reports Robust Q3'26 PAT Growth and Declares Interim Dividend
Sanofi India Ltd · Outcome · 29 Oct 2026, 11:58 pm
Sanofi India Reports Robust Q3'26 PAT Growth and Declares Interim Dividend Sanofi India posted a 3.4% YoY rise in Q3'26 revenue from operations to ₹4,917 million, with domestic sales up 2% and diabetes insulin growing 9% YoY. Profit Before Tax surged 54.2% YoY to ₹1,577 million, supported by an 8% drop in operating expenses and favorable mix. Net profit rose 53.6% YoY to ₹1,167 million, with EPS reaching ₹50.67 versus ₹32.99 in Q3'25. The board declared an interim dividend of ₹75 per equity share, setting the record date as 5th Nov'26.
Original exchange filing (PDF)
More announcements from Sanofi India Ltd
- Kindly refer the attachment · 18 Nov 2026
- Kindly refer the attachment · 30 Oct 2026
- Kindly refer the attachment · 30 Oct 2026
- Kindly refer the attachment · 30 Oct 2026
- Kindly refer the attachment · 30 Oct 2026
- Kindly refer the attachment · 30 Oct 2026
- Kindly refer the attachment · 30 Oct 2026
- Kindly refer the attachment · 29 Oct 2026
